Alishba Inshal Qasim on Muck Rack

Alishba Inshal Qasim

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Alishba Inshal

Contact Alishba Inshal, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Zepbound: A novel pharmacological approach to Obstructive Sleep Apnea management

|
By Muhammad Aamir, Hamdard College, Dania Nadeem, Alishba Inshal Qasim
| jpma.org.pk
Abstract Dear editor, In December 2024, the U.S. Food and Drug Administration (FDA) approved Zepbound (Tirzepatide) for the treatment of obstructive sleep apnea (OSA).(1) Tirzepatide is a dual receptor agonist for glucagon-like peptide-1 (GLP-1)and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, both of which are incretin hormones.
Open in Who Shared Issue with article?
See all 1 licensed articles (2 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified